Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

42.34
+0.16000.38%
Post-market: 42.340.00000.00%16:04 EDT
Volume:294.83K
Turnover:12.48M
Market Cap:1.78B
PE:-15.58
High:42.74
Open:42.36
Low:41.50
Close:42.18
Loading ...

Stock Track | Tarsus Pharmaceuticals (TARS) Stock Surges 5.4% in Pre-Market on Strong XDEMVY Launch

Stock Track
·
25 Feb

Tarsus Pharmaceuticals Q4 GAAP EPS $(0.60) Beats $(0.75) Estimate, Sales $66.41M Beat $58.33M Estimate

Benzinga
·
25 Feb

BRIEF-Tarsus Pharmaceuticals Q4 Basic EPS USD -0.6

Reuters
·
25 Feb

Tarsus Pharmaceuticals Inc: Qtrly REV $66.4 Mln

THOMSON REUTERS
·
25 Feb

Tarsus Pharmaceuticals Q4 Operating Expenses USD 90.829 Million

THOMSON REUTERS
·
25 Feb

Tarsus Pharmaceuticals Inc Q4 Shr View $-0.74, REV View $58.3 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
25 Feb

Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements

GlobeNewswire
·
25 Feb

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies’ Board of Directors at 2025 Annual Meeting

Business Wire
·
19 Feb

Is Tarsus Pharmaceuticals (NASDAQ:TARS) Using Too Much Debt?

Simply Wall St.
·
08 Feb

Strong Growth Prospects and Market Expansion Drive Buy Rating for Tarsus Pharmaceuticals

TIPRANKS
·
05 Feb

BofA Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $74

MT Newswires Live
·
03 Feb

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire
·
31 Jan

Tarsus Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
27 Jan

Tarsus Pharmaceuticals price target raised to $62 from $60 at Barclays

TIPRANKS
·
27 Jan

Barclays Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
27 Jan

CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last?

Zacks
·
23 Jan

Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer

Dow Jones
·
22 Jan

Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $72 From $65, Keeps Outperform Rating

MT Newswires Live
·
22 Jan